The lowest dose of letrozole that has been studied in clinical trials is 0.1 mg per day, though the smallest commercially available tablet is 2.5 mg. Doses as low as 0.25 mg taken three times per week have been tested in research settings, and even those achieved significant estrogen suppression. The answer depends on whether you’re asking about the lowest manufactured dose, the lowest dose that works, or the lowest dose prescribed in practice.
Lowest Dose Tested in Clinical Trials
The FDA prescribing information for letrozole (brand name Femara) reports that daily doses ranging from 0.1 mg to 5 mg suppress the hormones estradiol, estrone, and estrone sulfate by 75% to 95% from baseline in postmenopausal women. Even at 0.1 mg, the drug had measurable effects on estrogen levels. However, doses of 0.5 mg and higher pushed estrogen markers below detectable levels in many patients, and that suppression held steady throughout treatment.
In a large randomized trial of 555 postmenopausal women with advanced breast cancer, researchers directly compared 0.5 mg daily to the standard 2.5 mg daily. The 2.5 mg dose produced a slightly higher response rate (19.5% vs. 16.7%) and longer median disease control (21 months vs. 18 months). Both doses suppressed serum estrogen to a similar degree on lab tests, but the assays used were not sensitive enough to reliably detect small differences between the two. Based on this evidence, 2.5 mg was selected as the standard dose.
Intermittent Low-Dose Schedules
A randomized, double-blind trial at the Mayo Clinic tested whether taking letrozole less frequently could work just as well. The study assigned 112 postmenopausal women at increased breast cancer risk to one of four groups: the standard 2.5 mg daily, 2.5 mg three days a week (Monday, Wednesday, Friday), 1.0 mg three days a week, or 0.25 mg three days a week. Participants took their assigned regimen for 24 weeks.
All four groups achieved significant estrogen suppression, with estradiol dropping 75% to 78% and estrone dropping 86% to 93% from baseline. There were no meaningful differences between groups in side effects, bone turnover markers, cholesterol levels, or quality of life. The researchers concluded that low, intermittent doses were not inferior to the standard daily dose for suppressing estrogen. The 0.25 mg three-times-weekly schedule works out to an average of roughly 0.1 mg per day, making it the lowest effective regimen studied in a controlled trial.
Standard Dose for Breast Cancer
The only commercially manufactured tablet is 2.5 mg, and this is the FDA-approved dose for breast cancer treatment. It is taken once daily, with or without food. Letrozole has a long half-life of about two days, which means it builds up in your system and stays active between doses. This pharmacokinetic profile is part of why intermittent dosing schedules can still maintain estrogen suppression.
If your oncologist prescribes letrozole for breast cancer, the standard protocol is 2.5 mg once a day. Getting a lower dose would require either splitting tablets or having a compounding pharmacy prepare custom doses, neither of which is part of routine clinical practice for cancer treatment. The intermittent dosing research is promising but has not yet changed standard prescribing guidelines.
Doses Used for Ovulation Induction
For fertility treatment, letrozole is used very differently than in breast cancer. Rather than long-term daily use, it is taken for a short window of about five days early in the menstrual cycle to stimulate ovulation. The starting dose in fertility protocols is 2.5 mg per day for five days. If that doesn’t trigger ovulation, the dose is typically increased in steps to 5 mg, then 7.5 mg, and occasionally up to 10 mg daily. No fertility protocols use doses lower than 2.5 mg per day, because the goal is a brief, potent hormonal shift rather than sustained suppression.
Doses Used in Pediatric Cases
In children, letrozole is sometimes prescribed off-label for conditions like precocious puberty associated with McCune-Albright syndrome. Published case series have used doses as low as 1.25 mg per day in young girls, with some patients eventually reducing to 1.25 mg every other day after their symptoms improved. When puberty progressed despite the lower dose, clinicians typically increased to 2.5 mg daily. These pediatric doses are the lowest used in any clinical setting outside of experimental cancer prevention trials.
Why Lower Doses Are Not Widely Available
Because the only commercial tablet is 2.5 mg, any dose below that requires workarounds. Tablet splitting is imprecise, and letrozole tablets are small and not scored, making accurate halving difficult. Compounding pharmacies can prepare custom capsules in lower strengths, but this adds cost and is rarely covered by insurance. For most patients taking letrozole for breast cancer, the clinical evidence supporting 2.5 mg daily is strong enough that lower doses are not part of standard care, even though research suggests they may suppress estrogen almost as effectively.
If side effects like joint pain or bone density loss are a concern, the intermittent dosing data offers a useful conversation starter with your prescribing doctor. A three-times-weekly schedule at the standard 2.5 mg tablet strength would be the most practical way to reduce your total weekly dose without needing compounded medications.